Volume 27, Number 6—June 2021
Research
Twenty-Year Public Health Impact of 7- and 13-Valent Pneumococcal Conjugate Vaccines in US Children
Matt Wasserman
, Ruth Chapman, Rotem Lapidot, Kelly Sutton, Desmond Dillon-Murphy, Shreeya Patel, Erica Chilson, Vincenza Snow, Raymond Farkouh, and Stephen Pelton
, Ruth Chapman, Rotem Lapidot, Kelly Sutton, Desmond Dillon-Murphy, Shreeya Patel, Erica Chilson, Vincenza Snow, Raymond Farkouh, and Stephen Pelton
Table 3
Estimated average incidence of otitis media cases and visits averted by PCVs, United States, 1997–2019*
| Measure | 1997–1999 | 2000–2009 | 2010–2019 | Cumulative |
|---|---|---|---|---|
| Average incidence of visits per 100 children | 78 | 59 | 46 | NA |
| Expected visits† | NA | 154,269,900 | 155,511,917 | 309,781,817 |
| Estimated visits | NA | 119,429,938 | 93,025,190 | 212,455,128 |
| Visits averted‡ | NA | 34,839,962 | 62,486,726 | 97,326,688 |
*Values are rounded to the nearest whole numbers. PCV7 was approved for use in the United States in 2000; PCV13 was approved for use in the United States in 2010. NA, not applicable; PCV, pneumococcal conjugate vaccine; PCV7, 7-valent PCV; PCV13, 13-valent PCV. †Visits expected if PCVs had not been introduced. ‡Calculated by subtracting estimated visits from expected visits.
Page created: April 15, 2021
Page updated: May 18, 2021
Page reviewed: May 18, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.